Navigation Links
Compendia Bioscience Announces Collaboration with MDS Pharma Services to Deliver Novel Solution for Oncology Drug Development
Date:4/28/2009

ANN ARBOR, Mich., April 28 /PRNewswire/ -- Compendia Bioscience today announced a strategic collaboration with MDS Pharma Services to deliver OncoPredictor(SM) -- a novel solution for improved cancer drug development. OncoPredictor(SM) combines MDS Pharma Services OncoPanel(TM) with Compendia Bioscience's Oncomine(TM) for a solution that will provide guidance on patient groups most likely to respond to a new cancer therapy.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070213/NYTU093LOGO )

MDS Pharma Services OncoPanel(TM) service provides high content screening of up to 240 cancer cell lines to assess the cytotoxicity and chemotherapeutic potential of specific cancer drugs and drug combinations. Compendia's Oncomine(TM), a database of cancer genomic profiles coupled with an analysis web application, provides genomic characterization and comparison of cancer cell lines to 2,000 disease signatures from more than 27,000 reference patients based on molecular, pathological and histological sub-types. Through this collaboration, the OncoPredictor(SM) system will enable the analysis of drug sensitivity and resistance of novel drugs and drug combinations as well as the identification of associations with both disease sub-types and underlying tumor biology.

"Based on our experience working with 15 of the top 20 companies pursuing the development of cancer treatments, we believe this integrated solution could revolutionize cancer genomics for drug development," said Compendia CEO and Co-founder Dan Rhodes, Ph.D. "All of our customers are keenly interested in identifying which patients are mostly likely to respond to their new drugs. OncoPredictor(SM) provides the right experimental scale, in terms of cell line data and reference patient data, to deliver the answers our customers are seeking."

MDS Pharma Services is the only contract research organization with firsthand experience of delivering high quality cellular data on such a large scale using the exact growth and culture conditions from which the genomic data in Oncomine(TM) was generated.

"MDS Pharma Services clearly provides unique experience and capabilities," continued Rhodes. "We do not believe we could have identified a better partner to co-develop this solution."

The solution will be delivered as a stand-alone, end-to-end service and will not require a license to any of Compendia's Oncomine offerings.

"MDS Pharma Services is pleased to collaborate with Compendia Bioscience to develop OncoPredictor(SM), which will help clients developing cancer treatments to do so more effectively and quickly," said David Spaight, MDS Pharma Services president. "Compendia Bioscience is a leader in the field of cancer genomics and Oncomine(TM) has become a standard platform in the industry. We believe our joint solution - OncoPredictor(SM) - can also become an industry standard in oncology drug development at a cost affordable for both large and smaller companies"

About Compendia Bioscience's Oncomine(TM)

Oncomine(TM) combines a rapidly growing compendium of 30,000+ expertly curated cancer genomic profiles with a sophisticated analysis engine and a powerful web application for data mining and visualization. Oncomine(TM) facilitates target discovery and validation and supports the prioritization of tumor populations for drug development. http://www.compendiabio.com/products/products.htm

About Compendia Bioscience, Inc.

Compendia Bioscience is dedicated to harnessing the global collection of high throughput molecular data to provide researchers with the data and analysis tools necessary to validate biomarker and gene target discoveries, better understand mechanisms of disease, and optimize clinical outcomes. www.compendiabio.com

About MDS Pharma Services OncoPanel(TM)

MDS Pharma Services' OncoPanel(TM) offers high-throughput cellular drug profiling, relying on deep experience in cell culture and high content imaging to systematically screen compounds across hundreds of cancer cell lines simultaneously.

About MDS Pharma Services

MDS Pharma Services is committed to delivering quality service on time. We offer a full spectrum of resources to meet the drug discovery and development needs of the pharmaceutical and biotechnology industries. With numerous facilities strategically located around the world, we apply advanced scientific and technological expertise throughout the drug discovery and development process - from lead optimization, pre-IND research, early clinical research (bioequivalence, phases I-IIa) and bioanalysis through to global clinical development (phases IIb-IV), central lab and centralized cardiac services.

MDS Pharma Services Pharmacology/DMPK division, offers biochemical, cellular/functional, ADME/DMPK and in vivo assays for use in identifying lead compounds, profiling for selectivity, determining the potential for adverse events, evaluating efficacy and establishing proof of concept. To help speed lead optimization earlier in the discovery phase and streamline the surest path to clinic, the team offers extensive capabilities in molecular and cellular pharmacology, including more than 800 assays, multiple assay methodologies, high throughput screening with robotic automation, and expert assay development. To view the extensive catalog of discovery assays, visit the MDS Pharma Services' Pharmacology/DMPK Web site at http://discovery.mdsps.com/Catalog/.

For more information, visit our website at www.mdsps.com.


'/>"/>
SOURCE Compendia Bioscience, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Compendia Bioscience Releases Oncomine Concepts Edition 4.0
2. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM)
3. Stem Cell Biotherapy Sues Casey Nabavi, Co-Founder and Former President, for Conduct Resulting in Claims by SCB Patients Against Nabavi, Embezzling Money and Converting Other Assets Belonging to SCB and for Wrongfully Establishing Cellulogix Biosciences t
4. Coalition of Business, Labor, Academia and Bioscience Groups to Promote Medical Innovation, Spark Economic Growth
5. Business, Labor, Academia and Bioscience Groups to Launch New Coalition to Promote Medical Innovation and Spark Economic Growth
6. Epiphany Biosciences Initiates Program to Assess Valomaciclovir (EPB-348) as Adjunctive Therapy in Multiple Sclerosis (MS)
7. Pressure BioSciences, Inc. Provides Corporate Update
8. BIND Biosciences To Install First Siemens Simatic(R) PCS 7 Lab Process Control System in the U.S.
9. Cell Biosciences Announces First UK System Sale
10. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Revised Timing for Commercial Availability of Savella(TM)
11. PURE Bioscience Announces Brazilian Regulatory Approval for SDC-Based Hospital-Grade Disinfectants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... 26, 2017 , ... Mediaplanet is proud to announce the launch of its ... will educate readers on how to take care of all aspects of their skin. ... on melanoma. Dancing with the Stars professional, Witney Carson, shares her journey with the ...
(Date:5/26/2017)... ... May 26, 2017 , ... The Radiology Business ... focus on current legislative activity and the latest regulatory concerns impacting RBMA members. ... Sept. 10, and will continue through Monday, Sept. 11, at the Ritz-Carlton, Tysons ...
(Date:5/26/2017)... MN (PRWEB) , ... May 26, 2017 , ... A ... U.S. states with the healthiest seniors are located in the Midwest. With the average ... more and more people are concerned with both the quality and affordability of where ...
(Date:5/26/2017)... ... ... On May 24, the Congressional Budget Office (CBO) projected that the amended ... would result in 23 million Americans losing their health insurance by 2026 as compared ... Affordable Care Act (ACA). , “It is clear from the CBO analysis that ...
(Date:5/26/2017)... ... May 26, 2017 , ... Silver Birch of Hammond, a new assisted ... more than four acres of land at 5620 Sohl Avenue in Hammond, serves older ... building includes 125 studio and one-bedroom apartments. Each of the private apartments at Silver ...
Breaking Medicine News(10 mins):
(Date:5/15/2017)... , May 15, 2017 Enterin Inc., a ... and developing novel compounds to treat Parkinson,s disease (PD), ... study is a Phase 1/2a randomized, controlled, multicenter study involving ... It will enroll 50 patients over a 9-to-12-month period. The ... in 10 patients with PD. Participating sites include ...
(Date:5/10/2017)...  The Corporate Whistleblower Center says, "We are ... clinics to call us anytime at 866-714-6466 if they ... in a substantial scheme to overbill Medicare. We ... employee of a medical equipment company if their ... medical practice groups with extra generous incentives to use, ...
(Date:5/9/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... on the development of oral drug delivery systems, ... has granted Oramed a patent titled, "Methods and ... covers Oramed,s invention of an oral glucagon-like peptide-1 ... hormone that stimulates the secretion of insulin from ...
Breaking Medicine Technology: